in ,

Cell Line Development Market Forecast 2022-2032

Photo by CDC on Unsplash

According to FMI research, the global cell development line development market reached a valuation of 4.7 billion US dollars in 2022. The cell line development companies are further expected to grow by a CAGR of 5% per year from 2022-2032 making the total valuation of the market reach 7.66 billion Us dollars. In 2021 the market growth was estimated to be 4.4 billion dollars.

Prominent Drivers of the Market

Let’s dive into the factors that are responsible for the growth of the cell line development market.

Regenerative Medicine

The demand for regenerative medicine like stem cell transplants has surged in the past few years which has caused the shift in focus towards advanced research in oncology and increased the demand for biological pharmaceuticals.

The escalation in biopharma is due to the enhanced products of top players, manufacturers targeting the high-growth emerging markets like Asia, and increased investment in the research and development niche of the field.

Novel Technologies

Animal cells have been used for the production of monoclonal antibodies and recombinant proteins for years due to their rapid growth, high yield, and production optimization. The demand for cell culture, recombinant cell lines, and mammalian cell lines are increasing day by day which provides the opportunity for the growth of the field. The growth is expected to be supported by the use of human diploid cells in the production of various vaccines.

Advancements in culture technologies and innovative therapeutics with biosimilars also provide an opportunity for market growth.

The increased use of monoclonal antibodies to treat various diseases is also a growth driver. The increased demand for innovative and novel technologies will push the sales in the forecast period.

Challenges Faced by the Market

Although there is a significant increase in the reliability of cell line treatments, many challenges still need to be assuaged. The foremost challenge is the lack of understanding of cell line research. To make the cell line industry grow more, the fear of the unknown needs to be removed. More research is required to properly understand the functioning and mechanism of cell line treatments.

During cell line development, the chances of cross-contamination are increased which makes the whole process a little less reliable. Steps need to be taken to minimise the contamination risks.

The cost of setting up an animal culture lab to develop cell line therapies is sky high. The cost-effectiveness needs are brought under control so that the market can generate more revenue and expand accordingly.

Market Landscape

The US dominated the North American cell line development market by contributing 90.8% of the total market share. The growth of the healthcare sector in the US will further increase the cell line development market.

In Europe, Medical Tourism is increasing which is increasing the demand for cell line development services.

In China, the investments in biopharmaceuticals are increasing by the hour which is the major factor that is expected to contribute to the overall growth of the cell line development market around the globe. China held a 39.5% share of the whole market in APEJ in 2021 and is expected to grow at a 10% CAGR during the forecast period. The growth is attributed to increased government and private funding for biopharmaceuticals.

The Key Start-ups

A British startup called Rexgero is developing cell therapies for unmet medical needs. The eye-opening product REX-001 is a bone marrow-derived cell suspension with a high concentration of white blood cells. The therapy helps in Chronic Limb Ischemia by delivering immune cells to weakened vessels.

A US-based company Allogene Therapeutics develops allogeneic therapies for various cancers. The company uses alloCAR-T therapy to donate healthy cells of the donor to the diseased person. It is a startup pipeline that focuses on developing te=herapies for blood malignancies and solid tumours.

The US-based startup BlueRock Therapeutics is focusing most of its resources on regenerative medicine. The company uses bioprocessing to create cell banks from healthy donors. These cell banks are then used to turn into required cell lines for neurology, cardiology, haematology, etc.


Cell line therapies are the future and the key pharmaceutical competitors have realised this and are working on the research and better development of the field to stay at the top of medical and pharmaceutical trends.

Written by Marcus Richards


Leave a Reply

Your email address will not be published. Required fields are marked *



Prosoma Digital Therapeutics and EVERSANA Announce Commercialisation Partnership for New Therapeutic Supporting Mental Health and Behavioural Needs of Cancer Patients

Stuart McDowall Decreases Shareholdings in Criterium Energy Ltd.